利益相关者对适应性临床试验的看法:范围综述
该范围综述检索四个电子数据库并补充灰色文献,最终纳入18篇文献,分析医学试验社区中不同利益相关者对适应性设计(ADs)的态度、认知与理解。感知优势包括限制无效治疗和高效回答研究问题;障碍包括次要结局样本量不足、知情同意挑战、潜在偏倚、I类错误风险、设计与实施成本时间、使用理由不明确以及缺乏教育。患者视角在文献中明显缺失,不同利益相关者群体间认知存在差异。
要点
- 利益相关者认可ADs在限制无效治疗和提升研究效率方面的优势。
- 主要障碍包括样本量不足、知情同意困难、偏倚风险、I类错误风险及成本时间挑战。
- 患者视角在现有文献中明显缺失,各利益相关群体认知存在差异。
核心结论
- 利益相关者对适应性设计存在多样认知,需要进一步培训、指南和工具包以克服感知障碍。
- 除主要研究者外,患者、临床医生及参与日常实施的工作人员也应接受教育。
研究设计与样本
- 范围综述,检索四个电子数据库并补充网络灰色文献,最终纳入18篇文章进行分析。
主要发现
- 感知优势包括限制无效治疗和高效回答研究问题。
- 感知障碍包括次要结局样本量不足、知情同意挑战、潜在偏倚、I类错误风险、适应性设计成本和时间、使用理由不明确及缺乏教育。
- 不同利益相关者群体的认知存在差异,患者视角在文献中明显缺失。
临床怎么用
- 在采用适应性设计时需关注次要结局样本量、知情同意流程、偏倚与I类错误风险以及成本时间投入。
- 应加强对主要研究者、患者、临床医生及实施人员的适应性设计教育培训。
局限性
- 患者视角在纳入文献中明显缺失,可能限制对利益相关者认知的全面理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adaptive clinical trials (ACTs) represent an emerging approach to trial design where accumulating data are used to make decisions about future conduct. Adaptations can include comparisons of multiple dose tiers, response-adaptive randomization, sample size re-estimation, and efficacy/futility stopping rules. The objective of this scoping review is to assess stakeholder attitudes, perspectives, and understanding of adaptive trials. METHODS: We conducted a review of articles examining stakeholders encompassing the broad medical trial community's perspectives of adaptive designs (ADs). A computerized search was conducted of four electronic databases with relevant search terms. Following screening of articles, the primary findings of each included article were coded for study design, population studied, purpose, and primary implications. RESULTS: Our team retrieved 167 peer-reviewed titles in total from the database search and 5 additional titles through searching web-based search engines for gray literature. Of those 172 titles, 152 were non-duplicate citations. Of these, 119 were not given full-text reviews, as their titles and abstracts indicated that they did not meet the inclusion criteria. Thirty-three articles were carefully examined for relevance, and of those, 18 were chosen to be part of the analysis; the other 15 were excluded, as they were not relevant upon closer inspection. Perceived advantages to ADs included limiting ineffective treatments and efficiency in answering the research question; -perceived barriers included insufficient sample size for secondary outcomes, challenges of consent, potential for bias, risk of type 1 error, cost and time to adaptively design trials, unclear rationales for using Ads, and, most importantly, a lack of education regarding ADs among stakeholders within the clinical trial community. Perceptions among different types of stakeholders varied from sector to sector, with patient perspectives being noticeably absent from the literature. CONCLUSION: There are diverse perceptions regarding ADs among stakeholders. Further training, guidelines, and toolkits on the proper use of ADs are needed at all levels to overcome many of these perceived barriers. While education for principal investigators is important, it is also crucial to educate other groups in the community, such as patients, as well as clinicians and staff involved in their daily implementation.
引用
- Madani Kia T, Marshall JC, Murthy S, et al. Stakeholder perspectives on adaptive clinical trials: a scoping review. Trials. 2020. PMID: 32552852. doi:10.1186/s13063-020-04466-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。